Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Peter T. Doohan"'
Autor:
Thomas Harman, Michael Udoh, Dan L. McElroy, Lyndsey L. Anderson, Richard C. Kevin, Samuel D. Banister, Adam Ametovski, Jack Markham, Chris Bladen, Peter T. Doohan, Quentin Greba, Robert B. Laprairie, Terrance P. Snutch, Iain S. McGregor, John G. Howland, Jonathon C. Arnold
Publikováno v:
Frontiers in Physiology, Vol 14 (2023)
Background: T-type Ca2+ channels (Cav3) represent emerging therapeutic targets for a range of neurological disorders, including epilepsy and pain. To aid the development and optimisation of new therapeutics, there is a need to identify novel chemical
Externí odkaz:
https://doaj.org/article/8b1b021c9bdb4638b63894720a9176fe
Autor:
Danielle McCartney, Richard C. Kevin, Anastasia S. Suraev, Ayshe Sahinovic, Peter T. Doohan, Miguel A. Bedoya‐Pérez, Ronald R. Grunstein, Camilla M. Hoyos, Iain S. McGregor
Publikováno v:
Drug Testing and Analysis. 15:334-344
A growing number of clinical trials (CTs) are investigating the therapeutic potential of cannabidiol (CBD), a non-intoxicating phytocannabinoid found in Cannabis sativa. These CTs often use crossover experimental designs requiring 'washout' (clearanc
Autor:
Danielle McCartney, Anastasia S Suraev, Peter T Doohan, Christopher Irwin, Richard C Kevin, Ronald R Grunstein, Camilla M Hoyos, Iain S McGregor
Publikováno v:
Journal of Psychopharmacology. 36:1338-1349
Background: Cannabidiol (CBD), a major cannabinoid of Cannabis sativa, is widely consumed in prescription and non-prescription products. While CBD is generally considered ‘non-intoxicating’, its effects on safety-sensitive tasks are still under s
Autor:
Nicole A. Hawkins, Jonathon C. Arnold, Michael T. Bowen, Jennifer A. Kearney, Mary Chebib, Fan Zhang, Iain S. McGregor, Marika Heblinski, Dilara Bahceci, Lyndsey L. Anderson, Nathan L. Absalom, Melissa J. Benson, Peter T. Doohan
Publikováno v:
British Journal of Pharmacology. 178:4826-4841
Background and purpose Cannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval of cannabidiol (CBD) for the treatment of Dravet syndrome. Unregulated artisanal cannabis-based products used to treat child
Autor:
Richard C. Kevin, Jonathon C. Arnold, Iain S. McGregor, Peter T. Doohan, Lyndsey L. Anderson, Maximus Berger, G. Paul Amminger, Lachlan D. Oldfield
Publikováno v:
Journal of Clinical Psychopharmacology. 41:525-533
Background Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits anxiolytic properties in preclinical and human studies and is of interest as a novel intervention for treating anxiety disorders. Existing first-line pharmacother
Publikováno v:
Cannabis and cannabinoid research.
Autor:
G. Paul Amminger, Maximus Berger, Rebecca Vogel, Richard C. Kevin, Peter T. Doohan, Iain S. McGregor
Publikováno v:
Drug Testing and Analysis. 13:614-627
Cannabidiol (CBD) and Δ9 -tetrahydrocannabinol (THC) are the two best known and most extensively studied phytocannabinoids within Cannabis Sativa. An increasing number of pre-clinical studies and clinical trials have been conducted with one or both
Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial
Autor:
Ayshe Sahinovic, Christopher Irwin, Peter T. Doohan, Richard C. Kevin, Amanda J. Cox, Namson S. Lau, Ben Desbrow, Nathan A. Johnson, Angelo Sabag, Matthew Hislop, Paul S. Haber, Iain S. McGregor, Danielle McCartney
Publikováno v:
Sports Medicine - Open. 8
Background Cannabidiol (CBD) has demonstrated anti-inflammatory, analgesic, anxiolytic and neuroprotective effects that have the potential to benefit athletes. This pilot study investigated the effects of acute, oral CBD treatment on physiological an
Publikováno v:
The AAPS Journal. 23
Medicinal cannabis use has increased exponentially with widespread legalization around the world. Cannabis-based products are being used for numerous health conditions, often in conjunction with prescribed medications. The risk of clinically signific
Autor:
Lyndsey L, Anderson, Peter T, Doohan, Lachlan, Oldfield, Richard C, Kevin, Jonathon C, Arnold, Maximus, Berger, G Paul, Amminger, Iain S, McGregor
Publikováno v:
Journal of clinical psychopharmacology. 41(5)
Cannabidiol (CBD), a major nonintoxicating constituent of cannabis, exhibits anxiolytic properties in preclinical and human studies and is of interest as a novel intervention for treating anxiety disorders. Existing first-line pharmacotherapies for t